Plain-English translation of NCT07221747 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether adding extra clinical support and counseling helps people in Malawi stick with cabotegravir long-acting injection, a new HIV prevention medication. The study will compare two approaches: standard care guidance versus an enhanced support package that includes additional clinical help and provider-focused strategies. Researchers want to understand what helps people continue taking this medication over time.
While this medication is effective at preventing HIV, many people stop taking it or switch to other forms. This trial exists to figure out what extra support—like counseling, monitoring visits, and better provider training—helps people stay committed to the treatment and get the full benefit.
You likely qualify if…
You likely don't qualify if…
If you join, you'll receive either standard HIV prevention care or standard care plus an enhanced support package that may include extra clinical visits, counseling, and safety monitoring. Your clinic will be randomly assigned to one of these two approaches. You'll be followed for at least 5 months from when you start the medication, with visits every 2–3 months for testing and check-ins. The study uses existing clinic data and records to track whether you continue the medication over time.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
Malawi
Sponsor
Georgetown University
Collaborators
Center for the Development of People, Centers for Disease Control and Prevention
Enrollment target
~9,900 participants
Started
February 2026
Primary completion
August 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
15 Years – 110 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Charles Holmes, MD, MPH
Georgetown University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.